M. Al-Adhami

发表

Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus

B. Bacon, M. Shiffman, N. Afdhal, 2007, Hepatology.

Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study

D. Cella, W. Lenderking, J. Nazir, 2022, Annals of Hematology.

A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).

M. Cotreau, M. Fishman, S. Srinivas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).

R. Motzer, C. Sternberg, W. Slichenmyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

D. Doval, W. Slichenmyer, R. Chacko, 2010 .

Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).

R. Chacko, P. Bhargava, O. Lipatov, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

730 Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response

B. Bacon, E. Masciari, P. Kwo, 2006 .

Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist

A. Vicari, A. Krieg, H. Davis, 2007, Antiviral therapy.

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

H. Scher, A. Armstrong, B. Tombal, 2019, JAMA oncology.

Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria

E. Roman, T. Numbenjapon, E. Tse, 2022, Annals of Hematology.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

J. Kutok, H. Nevanlinna, J. Bartek, 2012, Human pathology.

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

C. Leichman, A. Krieg, V. Hirsh, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

M. Duh, R. Wong, K. Wilson, 2023, Advances in Therapy.

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

T. Ajayi, R. Wong, D. Gómez-Almaguer, 2021, Blood.

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.

J. Panse, J. Szer, A. Risitano, 2022, The Lancet. Haematology.

3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

J. Panse, J. Szer, A. Risitano, 2021, Experimental Hematology.

[649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA

E. Schiff, P. Kwo, D. Bright, 2007 .

Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC).

D. Doval, W. Slichenmyer, R. Chacko, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of a tivozanib response biomarker identified in a preclinical model with clinical activity in a phase II study in renal cell carcinoma (RCC).

W. Slichenmyer, M. Robinson, P. Bhargava, 2010 .

CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: A randomized phase II trial comparing two doses and in combination with DTIC

B. Redman, H. Zarour, J. Weber, 2005 .

CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study

J. Mezger, C. Manegold, D. Woytowitz, 2005 .

Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings

M. Al-Adhami, Stacie Lallier, R. Horneff, 2024, Research and practice in thrombosis and haemostasis.